Skip to main content
Signal8
Launch Terminal

GRAIL, Inc. (GRAL)

GRAIL, Inc., a commercial-stage healthcare company, provides multi-cancer early detection testing and services in the United States and internationally. It offers Galleri, a cancer screening test for asymptomatic individuals over 50 years of age; and a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients with clinical suspicion of cancer. The company also provides development services, including support for ongoing clinical studies, pilot testing, research, and therapy development. In addition, its precision oncology portfolio consists of n RUO-targeted methylation-based platform that enables applications for disease prognostication, risk stratification, minimal residual disease detection, and recurrence and relapse monitoring. The company was incorporated in 2015 and is headquartered in Menlo Park, California.

Sector: Services-Medical Laboratories

Industry: Medical - Diagnostics & Research

GRAIL Inc. logo

GRAIL Inc.

NASDAQ:GRALHealthcare
-9.75%$143.43
AH$144.00+0.40%vs close
Mkt Cap$6.41B
Float42.42M
O/S44.67M
Vol
$ Vol
RVOL
Inst Own85.7%
SI19.3%
Earnings
Dilution
GRAIL Inc. logoNASDAQ:GRAL$143.43-9.75%
Phase Distribution
8 lead-sponsored trials·4 active·2 completed
Not applicable8
(2 more as collaborator)
Status Overview
Recruiting1
Active, not recruiting3
Completed2
Unknown2

Trials need funding. See this company's dilution risk and cash position.

Clinical Trials
Sponsor role
Status
  • Observational
    Unknown status

    The Circulating Cell-free Genome Atlas Study

    -

    Neoplasms, Cancer

    Enrollment
    15,254
    Start
    Aug 2016
    Primary Completion
    Mar 2024est.
    Completion
    Mar 2024est.
    NCT02889978
  • Observational
    Completed

    The STRIVE Study: Development of a Blood Test for Early Detection of Multiple Cancer Types

    -

    Neoplasms, Cancer

    Enrollment
    99,481
    Start
    Feb 2017
    Primary Completion
    Jun 2022
    Completion
    Apr 2024
    NCT03085888
  • Not applicable
    Completed

    Assessment of the Implementation of an Investigational Multi-Cancer Early Detection Test Into Clinical Practice

    Multi-Cancer Early Detection Test

    Cancer

    Enrollment
    6,662
    Start
    Dec 2019
    Primary Completion
    Dec 2021
    Completion
    Jan 2022
    NCT04241796
  • Not applicable
    Active, not recruiting

    PATHFINDER 2: A Multi-Cancer Early Detection Study

    Multi-Cancer Early Detection Test

    Early Detection of Cancer, Cancer

    Enrollment
    35,883
    Start
    Dec 2021
    Primary Completion
    Feb 2026
    Completion
    Apr 2028est.
    NCT05155605
  • Observational
    Active, not recruiting

    REFLECTION: A Clinical Practice Learning Program for Galleri®

    MCED, SOC

    Early Detection of Cancer, Cancer

    Enrollment
    14,633
    Start
    Aug 2021
    Primary Completion
    Sep 2025
    Completion
    Oct 2026est.
    NCT05205967
  • Not applicable
    Active, not recruiting

    Does Screening With the Galleri Test in the NHS Reduce the Likelihood of a Late-stage Cancer Diagnosis in an Asymptomatic Population? A Randomised Clinical Trial

    Multi-cancer early detection test (Galleri test)

    Cancer

    Enrollment
    142,318
    Start
    Aug 2021
    Primary Completion
    Jun 2026
    Completion
    Jan 2031est.
    NCT05611632
  • Not applicable
    Recruiting

    Galleri® in the Medicare Population.

    Multi-Cancer Early Detection Test (Galleri®)

    Cancer

    Enrollment
    50,000
    Start
    Jul 2024
    Primary Completion
    Sep 2030est.
    Completion
    Sep 2030est.
    NCT05673018
  • Observational
    Unknown status

    The Galleri® Community Research Program

    -

    Data Collection

    Enrollment
    250
    Start
    Aug 2024
    Primary Completion
    Dec 2025est.
    Completion
    Dec 2025est.
    NCT06603259
Search ClinicalTrials.gov for “Grail”